Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

e-Poster Display Session

184P - Development and external validation of a nomogram to predict recurrence-free survival after R0 resection for stage II/III gastric adenocarcinoma: An international multicenter study

Date

22 Nov 2020

Session

e-Poster Display Session

Topics

Tumour Site

Gastric Cancer

Presenters

Bin-Bin Xu

Citation

Annals of Oncology (2020) 31 (suppl_6): S1287-S1318. 10.1016/annonc/annonc356

Authors

B. Xu1, Z. Xue1, D. Wu1, J. Lu1, M.J. Truty2, J. Xie1, J. Wang1, J. Lin1, Q. Chen1, L. Cao1, M. Lin1, R. Tu1, Z. Huang1, J. Lin1, H. Zheng1, P. Li1, C. Zheng1, C. Huang1

Author affiliations

  • 1 Department Of Gastric Surgery, Fujian Medical University Union Hospital, 350001 - Fuzhou/CN
  • 2 Section Of Hepatobiliary And Pancreatic Surgery, Division Of Subspecialty General Surgery, Department Of Surgery, Mayo Clinic, 55905 - Rochester/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 184P

Background

The benefit of adjuvant chemotherapy varies widely among patients with stage II/III gastric cancer (GC), and tools predicting outcomes for this patient subset are lacking. We aimed to develop and validate a nomogram to predict recurrence-free survival (RFS) and the benefits of adjuvant chemotherapy after radical resection in patients with stage II/III GC.

Methods

Data on patients with stage II/III GC who underwent R0 resection from January 2010 to August 2014 at Fujian Medical University Union Hospital (FMUUH) (n=1240; training cohort) were analyzed by Cox regression to identify independent prognostic factors for RFS. A nomogram including these factors was internally and externally validated in FMUUH (n=306) and a US cohort (n=111), respectively.

Results

The multivariable analysis identified age, differentiation, tumor size, number of examined lymph nodes, pT stage, pN stage, and adjuvant chemotherapy as associated with RFS. A nomogram including the above 7 factors was significantly more accurate in predicting RFS compared with the 8th AJCC-TNM staging system for patients in the training cohort. The risk of peritoneal metastasis was higher and survival after recurrence was significantly worse among patients calculated by the nomogram to be at high risk than those at low risk. The nomogram’s predictive performance was confirmed in both the internal and external validation cohorts.

Conclusions

A novel nomogram is available as a web-based tool and accurately predicts long-term RFS for GC after radical resection. The tool can also be used to determine the benefit of adjuvant chemotherapy by comparing scores with and without this intervention.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Scientific and Technological Innovation Joint Capital Projects of Fujian Province.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.